Pipeline products We aim to excel in innovation Pipeline tomeet patients signi cant unmetneeds.
In 2014 we continued to strengthen our pipeline through focused R&D andbusiness development.
Preclinical 33 preclinical research TH GCH1 SHP630 programs including: Gene Pod Parkinsons adRP Subset SHP619 SHP624 Duchennes Muscular SHP608 Heme B Gene Edit Dystrophy Dystrophic E. Bullosa SHP628 FT-061 SHP631 Renal Impairment Hunter syndrome Phase One SHP611 SHP616 CINRYZE SHP627 FT011 MLD Phase 1 2 Acute Neuromyelitis Focal Segmental Optica Glomerulosclerosis SHP616 CINRYZE SC SHP616 CINRYZE SHP626 LUM002 HAE Prophylaxis Paroxysmal Nocturnal Non-Alcoholic Hemoglobinuria Steatohepatitis SHP622 Friedreichs Ataxia Phase Two SHP602 SHP620 Maribavir SHP625 LUM001 Iron overload CMV in transplant patients Progressive Familial clinical hold Intrahepatic Cholestasis LDX Japan SHP610 ADHD SHP625 LUM001 Sanfi lippo A Alagille Syndrome SHP616 CINRYZE SHP609 Acute Antibody Mediated SHP625 LUM001 Hunter IT Rejection Primary Sclerosing Cholangitis SHP607 SHP625 LUM001 Prevention of ROP Primary Biliary Cirrhosis Phase Three FIRAZYR SHP555 US INTUNIV Japan ACE inhibitor-induced AE Chronic Constipation ADHD FIRAZYR Japan SHP606 li tegrast SHP465 HAE acute Dry eye disease ADHD SHP616 CINRYZE Japan HAE Prophylaxis Registration XAGRID Japan VPRIV Japan VYVANSE Thrombocythaemia Gaucher BED in adults Approved Q3 2014 Approved Q3 2014 Approved Q1 2015 INTUNIV EU ADHD Lisdexamfetamine dimesylate, active ingredient in VYVANSE 16 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Anticipated pipeline milestones.
2016 SHP606 li tegrast 2 Launch SHP625 LUM001 PSC Phase 2 head line data 2015 3 SHP625 LUM001 PFIC Phase 2 head line data SHP609 Phase 2 3 head line data SHP610 Phase 2B head line data SHP606 li tegrast SHP625 LUM001 NDA Filing PBC Phase 2 head line data SHP625 LUM001 SHP611 ALGS IMAGO study MLD Phase 1 2 head line data Phase 2 head line data SHP625 LUM001 VYVANSE ALGS ITCH study 1 BED in adults Launch Phase 2 head line data SHP620 Maribavir SHP607 Phase 2 head line data ROP Phase 2 head line data 1 VYVANSE BED in adults approved January 30, 2015.
3 Interim SHP625 PFIC INDIGO data expected Q2 2015.
ANNUAL REPORT 2014 SHIRE PLC 17 Strategic drivers Joseph Tauber, MD Tauber Eye Center, Kansas City, MO, US We make the most of our distinctive mix of businesses to drive continued growth.
In 2014 we added our new Ophthalmics business.
With the help of specialists such as Dr. Joe Tauber and Dr. Howard Mayer Shire, we are working on a number of developments in this specialist area, notably our potential treatments for Dry Eye Disease and for the prevention of retinopathy of prematurity ROP.
18 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Growth For Shire, growth is both a means and an end.
Sustained high growth across all our business units enables us to fuel further R&D and in turn develop innovative new products for patients with unmet needs.
Growth drives our revenues and pro ts.
Growth, too, is a great marker ofour progress, as we strive to achieve our 10 x 20 target to double our product 1 sales to $10 billion by 2020.
We are on track to le li tegrast in 2015, andrecently received FastTrack designation from the FDA onSHP607 Flemming Ornskov, CEO $5,830m 23% Product sales Product sales growth 6 $2,402m 2 Double digit growth products Non GAAP cash generation 1 Compared to 2013 product sales of $4.8 billion.
2 This is a Non GAAP financial measure.
For reconciliation to US GAAP please see page 166.
ANNUAL REPORT 2014 SHIRE PLC 19 Strategic drivers continued Innovation Innovation is the lifeblood of our current and future success.
We seek to focus our innovation across areas with high medical need.
To this end, we aim to expand our rare disease expertiseand offerings through research and partnerships, and toextend our existing portfolio ofproducts to new indications and therapeutic areas.
2014 Number of programs inpipeline as at December 31, 2014 Pre-clinical 33 Phase 1 7 60 Phase 2 11 Phase 3 7 Registration 2 $840m 2014 Investment in 1 NonGAAP R&D 1 This is a Non GAAP financial measure.
20 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Cindy Hahn Founder and CEO The Alagille Syndrome Alliance ALGSA With our focus on rare diseases and other specialty conditions we are always looking to build on our existing strengths and extend our expertise to new and complementary areas.
Through our acquisition of Lumena, for example, we are in clinical trials with SHP625 for the treatment of Alagille Syndrome, collaborating with patient advocates like Cindy to advance our understanding and capabilities and help patients in need.
ANNUAL REPORT 2014 SHIRE PLC 21 Strategic drivers continued Ef ciency Our ongoing focus on ef ciency enables us to reinvest in continued growth.
The leaner and more agile we are as an organization, the more able we are to fuel and ful l our purpose to enable people with life altering conditions to lead better lives.
Ongoing ef ciency program Integrated R&D under a single team Created a geographic footprint with two major hubs Streamlined other corporate functions and internal processes Divested non-core assets e. g. DERMAGRAFT Signi cant margin improvement 1,2 $ million: percent of product sales 2014 5,830 44% 27% 14% 14% 4,758 2013 38% 30% 19% 13% EBITDA SG&A R&D COGS 1 Results from continuing operations including ViroPharma Inc. and excluding DERMAGRAFT.
For reconciliation to US GAAP pleasesee page 166.
22 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Our new International Operational HQ Zug, Switzerland By maximizing effi ciency across Shire we free upgreater resources to focus on researching, developing and bringing to market much neededtreatments for patients.
One example ofimproved effi ciency is the consolidation of ourglobal hubs into our US Operational HQ in Lexington, MA andan International Operational HQin Zug, Switzerland.
ANNUAL REPORT 2014 SHIRE PLC 23 Strategic drivers continued People Our people are at the heart of our journey to become a leading biotech delivering innovative global medicines to patients with rare diseases and other specialty conditions.
We focus on attracting and retaining great people and giving them an environment where they are encouraged to excel.
Ongoing ef ciency program Foster and reward a high-performance culture Attract, develop and retain the best talent Live our values Overall gender breakdown as at December 31, 2014 2014 2,555 51% 2,461 49% 2013 2,736 51% 2,600 49% Male Female 2014 employment by region as at December 31, 2014 North America 3,532 Europe 1,168 Latin America 187 Other regions 129 24 SHIRE PLC ANNUAL REPORT 2014 Strategic Report Governance Financial Statements Other Information Members of the Rare Disease Business Unit, Zug, Switzerland From our new International Operational Headquarters in Zug, to our sales forces around the world, we work together as a close-knit, resilient team dedicated to achieving high performance.
Throughout Shire, we strive to create a great place to work, where people can perform and progress totheir full potential.
Our shared purpose is to help people with life-altering conditions lead better lives.
